GLP-1 explainers · Sponsored

Compounded Tirzepatide vs Zepbound: What Actually Differs

7 min read · updated October 19, 2026

Sponsored. This article features a product from Vea Health. We have a financial relationship with Vea Health. How we make money.

The brief

Zepbound is FDA-approved; compounded tirzepatide is not and is not reviewed by the FDA for safety, effectiveness or quality.¹
The 2,539-person SURMOUNT-1 trial tested the approved product; no trial of a compounded product was found.²³
The FDA has received reports of events possibly linked to dosing errors with compounded injectables.¹
The tirzepatide boxed warning and common gastrointestinal effects apply to both.⁴

Same drug name, different regulatory status. Here is what the label, the trial and the FDA say about each.

Zepbound is the FDA-approved brand of tirzepatide. Compounded tirzepatide is a pharmacy-prepared version made for an individual patient under a prescription. It is not FDA-approved, which means the FDA has not reviewed it for safety, effectiveness or quality before it is sold.¹ The large weight-loss trials were run on the approved product, not on compounded preparations, so what those trials found cannot be assumed to carry over.²³

How do compounded tirzepatide and Zepbound differ?

	Zepbound	Compounded tirzepatide
FDA status	FDA-approved for weight reduction and for obstructive sleep apnea in adults with obesity⁴	Not FDA-approved; not reviewed by the FDA for safety, effectiveness or quality¹
Trial evidence	SURMOUNT-1: 2,539 adults, 72 weeks²	No trial of a compounded product found; efficacy and safety "largely unknown" per a 2026 review³
Presentations	Single-dose pens and vials, multi-dose vials and a KwikPen, in fixed strengths⁴	Set by the compounding pharmacy; may be a multi-dose vial the patient draws up with a syringe¹
Dose steps	Starts at 2.5 mg weekly for 4 weeks, then rises in 2.5 mg steps after at least 4 weeks on a dose; maximum 15 mg weekly⁴	Set by the prescriber and pharmacy; the FDA has received reports of events linked to doses above the label¹
Added ingredients	Labeled formulation only⁴	Some products add vitamin B12 or other ingredients³
Oversight	FDA review and labeling	State-licensed pharmacy; mainly state boards of pharmacy⁵

What did the trials actually measure?

In SURMOUNT-1, 2,539 adults with obesity, or overweight plus a weight-related condition and no diabetes, were randomly assigned to weekly tirzepatide (5, 10 or 15 mg) or placebo for 72 weeks. Mean weight change at week 72 was -15.0%, -19.5% and -20.9% on the three doses, against -3.1% on placebo. Adverse events caused treatment to stop in 4.3% to 7.1% of the tirzepatide groups and 2.6% on placebo. The study was funded by Eli Lilly.²

Those results describe the approved product at labeled doses with a stepped escalation. They do not describe a vial from a given compounding pharmacy.

What are the specific quality and safety concerns?

Dosing errors. The FDA has received reports of adverse events, some requiring hospitalization, that may be related to patients measuring or self-administering the wrong dose from compounded injectables, and reports linked to doses beyond the approved label.¹
Vial handling. The FDA advises discarding a multi-dose vial 28 days after first use even if medication remains, and using a new sterile needle and syringe each time.¹
Shipping and storage. The FDA reports complaints of compounded injectables arriving warm or with inadequate ice packs and advises not using a product that arrives warm.¹
Combination products. A 2026 analysis by Eli Lilly scientists (a manufacturer of the approved drug, which readers should weigh) tested tirzepatide-B12 products from the U.S. market and found a previously unidentified impurity. The clinical effect of that impurity is unknown.⁶ A separate university review of 33 unique compounded products found little justification for added nutrients.³
Fraud. The FDA is aware of fraudulent products labeled as compounded tirzepatide, some naming pharmacies that do not exist.¹
Reporting. Pharmacies that are not outsourcing facilities do not have to submit adverse events to the FDA, so reports are likely undercounted. As of May 31, 2026, the FDA had received more than 730 reports tied to compounded tirzepatide.¹

The FDA says many reported events look like those of the approved drugs, and that it cannot always tell whether the drug caused them.¹

What stays the same?

Both are tirzepatide, so the class risks apply to both. The Zepbound label carries a boxed warning for thyroid C-cell tumors seen in rodents and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Its warnings also cover severe gastrointestinal reactions, kidney injury from dehydration and gallbladder disease.⁴ For a plain-language list, see our guide to GLP-1 side effects, and for the background see what tirzepatide is.

Our pick (sponsored): compounded tirzepatide from Vea Health

Compounded tirzepatide from Vea Health is our pick in this comparison because we have a financial relationship with Vea Health. That is the basis for the placement, not a test or a ranking of products. We make no claim that it is safer, stronger or better than Zepbound or any other provider.

Vea Health says it offers compounded tirzepatide injections, prescribed only after a licensed clinician reviews an online health questionnaire, and that a patient is not charged unless a clinician approves the prescription.⁷ It suits a reader who has talked with a clinician, understands that the product is compounded and not FDA-approved, and prefers an online consultation. It is not a fit for anyone whose clinician would choose the approved product, and the clinician can decline. We did not find a source comparing Vea's product with Zepbound, so we do not state a difference beyond regulatory status and format.

How should you choose?

The FDA states that compounded drugs should be used only when a patient's medical needs cannot be met by an FDA-approved drug.¹ Questions worth putting to any provider:

Which state-licensed pharmacy prepares it, and does the label show its name?
Is it tirzepatide alone, or combined with B12 or other ingredients?
How is each dose measured, and who explains the syringe markings?
What is the starting dose and the step schedule, and how does it compare with the Zepbound label?
Who answers questions after the medication arrives?

The FDA lists as warning signs a company that claims the compounded drug is the same as the approved one, offers deep discounts, or does not require screening and a prescription from a licensed doctor.¹ Our explainer on compounded GLP-1s covers the basics.

Bottom line. Zepbound is FDA-approved; compounded tirzepatide is not and is not reviewed by the FDA for safety, effectiveness or quality.¹

Important safety information. The FDA label for tirzepatide carries a boxed warning about thyroid C-cell tumors seen in rodents; it should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.⁸ The most common side effects are nausea, diarrhea, vomiting and constipation.⁸ Serious risks include pancreatitis, gallbladder problems and low blood sugar when combined with insulin or sulfonylureas.⁸ Compounded versions are not FDA-approved.¹ Only a licensed clinician should decide whether it is appropriate for you.

Quick questions

Is compounded tirzepatide the same as Zepbound?

It may share the active ingredient, but it is not the same product. Zepbound is FDA-approved and was studied in large trials. Compounded tirzepatide is not FDA-approved and has not been reviewed by the FDA for safety, effectiveness or quality.

Is compounded tirzepatide FDA-approved?

No. The FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.

Why do compounded tirzepatide doses cause concern?

The FDA has received reports of adverse events that may be linked to patients drawing up the wrong dose from vials and to doses above the approved label. Always confirm the dose and syringe markings with the prescriber or pharmacy.

Does compounded tirzepatide contain B12?

Some products do. A 2026 review of 33 unique compounded semaglutide and tirzepatide products found 48% combined the drug with ingredients such as cyanocobalamin, and saw little justification for the additions.

Does Zepbound come in vials?

Yes. The Zepbound label lists single-dose pens and vials, multi-dose vials and a single-patient-use KwikPen.

More briefs

Sources

U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. PubMed 35658024.
Belcourt J, et al. Compounded semaglutide and tirzepatide products use unique formulations but efficacy and safety largely unknown. Ann Pharmacother. 2026. PubMed 41689811.
Eli Lilly. ZEPBOUND (tirzepatide) prescribing information. DailyMed, U.S. National Library of Medicine.
U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
Jordan B, et al. A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications. Expert Opin Drug Saf. 2026. PubMed 42010938.
Vea Health. Tirzepatide intake. Accessed October 9, 2026.
Tirzepatide prescribing information. DailyMed, U.S. National Library of Medicine.